Stenotrophomonas maltophilia is a Gram-negative, biofilm-forming bacterium. Although generally regarded as an organism of low virulence, S. maltophilia is an emerging multi-drug resistant opportunistic pathogen in hospital and community settings, especially among immunocompromised hosts. Risk factors associated with S. maltophilia infection include underlying malignancy, cystic fibrosis, corticosteroid or immunosuppressant therapy, the presence of an indwelling central venous catheter and exposure to broad spectrum antibiotics. In this review, we provide a synthesis of information on current global trends in S. maltophilia pathogenicity as well as updated information on the molecular mechanisms contributing to its resistance to an array of antimicrobial agents. The prevalence of S. maltophilia infection in the general population increased from 0.8–1.4% during 1997–2003 to 1.3–1.68% during 2007–2012. The most important molecular mechanisms contributing to its resistance to antibiotics include β-lactamase production, the expression of Qnr genes, and the presence of class 1 integrons and efflux pumps. Trimethoprim/sulfamethoxazole (TMP/SMX) is the antimicrobial drug of choice. Although a few studies have reported increased resistance to TMP/SMX, the majority of studies worldwide show that S. maltophilia continues to be highly susceptible. Drugs with historically good susceptibility results include ceftazidime, ticarcillin-clavulanate, and fluoroquinolones; however, a number of studies show an alarming trend in resistance to those agents. Tetracyclines such as tigecycline, minocycline, and doxycycline are also effective agents and consistently display good activity against S. maltophilia in various geographic regions and across different time periods. Combination therapies, novel agents, and aerosolized forms of antimicrobial drugs are currently being tested for their ability to treat infections caused by this multi-drug resistant organism.
1 December 2019 in Journal of Microbiology, Immunology and Infection
In Southeast Asia, Japanese encephalitis (JE) is an important cause of viral encephalitis which may cause severe neurological sequelae. JE affects mostly children; therefore, clinical presentations and prognosis of adult JE patients are seldom addressed. This study aimed to describe the clinical characteristics and prognostic factors for the outcome of adult JE patients. Medical records of adult JE patients with acute encephalitis syndrome during 2001-2018 from five medical centers in southern Taiwan were reviewed. Clinical characteristics, brain images, and prognostic factors for outcomes were analyzed. Patients were divided into the good outcome (GO) group and poor outcome (PO) group according to their Glasgow Coma Scale (GCS) scores (GCS >8 vs. ≤ 8) at discharge. Sixty-eight patients (men, 61.8%; median age, 50 years) were included. Summer is the epidemic season, and the number of cases peaked in June. The most common symptoms at initial presentation were altered consciousness and fever (both 94.1%), followed by headache (51.4%). The most commonly involved brain regions were thalamus (55.7%) and basal ganglion (37.7%). The median GCS score at nadir was 8, and the median time from onset to nadir was five days. Fifty-two patients were included in the GO group, while 16 were included in the PO group. On multivariate analysis, flaccidity, rigidity, and elevated CSF protein level were identified as independent prognostic factors for PO. Initial clinical presentations of abnormal muscle tone including flaccidity, rigidity and high CSF protein levels are independent prognostic factors for PO in adult JE patients.
Carbapenem-resistant Enterobacteriaceae (CRE) is listed as an urgent threat by the World Health Organization because of the limited therapeutic options, rapid evolution of resistance mechanisms, and worldwide dissemination. Colistin is a common backbone agent among the “last-resort” antibiotics for CRE; however, its emerging resistance among CRE has taken the present dilemma to the next level. Azidothymidine (AZT), a thymidine analog used to treat human immunodeficiency virus/acquired immunodeficiency syndrome, has been known to possess antibacterial effects against Enterobacteriaceae. In this study, we investigated the combined effects of AZT and colistin in 40 clinical isolates of colistin-resistant, carbapenem-resistant K. pneumoniae (CCRKP). Eleven of the 40 isolates harbored Klebsiella pneumoniae carbapenemase. The in vitro checkerboard method and in vivo nematode killing assay both revealed synergistic activity between the two agents, with fractional inhibitory concentration indexes of ≤0.5 in every strain. Additionally, a significantly lower hazard ratio was observed for the nematodes treated with combination therapy (0.288; p < 0.0001) compared with either AZT or colistin treatment. Toxicity testing indicated potentially low toxicity of the combination therapy. Thus, the AZT–colistin combination could be a potentially favorable therapeutic option for treating CCRKP.
The most optimal treatment for serious Stenotrophomonas maltophilia infections remains undetermined based on current evidence. The evolution of Infectious Diseases Society of America (IDSA) guidance from 2022 to 2024 reflects growing support for combination therapy and a shift away from agents with unfavorable pharmacokinetic/pharmacodynamic profiles, such as tigecycline. No randomized controlled trials (RCTs) have been conducted to date, and existing observational comparative studies have yielded heterogeneous results. Despite efforts to adjust for bias and confounders, definitive conclusions remain elusive, largely due to methodological limitations inherent in retrospective designs, such as immortal time bias. For serious S. maltophilia infections, a multi-arm trial is likely necessary to generate robust evidence; however, challenges, such as large sample size requirements, difficult patient recruitment, and high implementation costs remain significant barriers. To overcome these obstacles, innovative trial designs and analytic approaches have emerged. Target trial emulation, for instance, seeks to approximate RCT-level evidence using observational data. Several other designs aim to improve the flexibility and efficiency of clinical trials, including: multi-arm, multi-stage (MAMS) trial designs; embedding a multi-arm trial within a larger platform trial; an analysis method known as PRACTical method composed of personalized randomization treatment options relevant to individuals; and Bayesian analytic frameworks, enabling simultaneous comparison across multiple treatment arms. As we seek answers to complex clinical dilemmas, such as the life-threatening S. maltophilia infection reported by Qadabashi and colleagues in a recent article in ASM Case Reports (ASM Case Rep 1:e00005-25, 2025, https://doi.org/10.1128/asmcr.00005-25 ), these forward-looking trial designs and analytic methodologies will be critical in shaping the future of evidence-based treatment strategies.
27 August 2025 in Journal of Microbiology, Immunology and Infection
Third-generation cephalosporin-resistant Enterobacterales is a recognized global concern. This study investigated the molecular epidemiology of β-lactamase genes and antimicrobial susceptibility patterns among ceftriaxone-resistant Enterobacterales causing intra-abdominal and urinary tract infections in Taiwan between 2009 and 2019. Data from the SMART surveillance program were analyzed, including Enterobacterales isolates with ceftriaxone minimum inhibitory concentrations ≥4 μg/mL. β-lactamase genes were detected using multiplex polymerase chain reaction assays. The overall ceftriaxone-resistant rate among Enterobacterales was 28.2 %, with a significant annual increase in ceftriaxone-resistant Klebsiella pneumoniae in both community- and hospital-acquired infections. Among the 2614 ceftriaxone-resistant isolates, the most common species were Escherichia coli (58.4 %), K. pneumoniae (16.3 %), and Enterobacter cloacae (9.9 %). Of all ceftriaxone-resistant isolates, 27.8 % carried only AmpC genes, 38.8 % carried only ESBL genes, and 16.2 % harbored both. High carriage rates of AmpC-encoding genes were observed in E. coli (38.9 %) and K. pneumoniae (48.9 %), with an overall prevalence of 44 %. The most common genotypes were blaCMY (41.2 %), blaDHA (31.8 %), and blaACT/blaMIR (27 %). Ceftolozane/tazobactam showed poor susceptibility against ceftriaxone-resistant isolates carrying only AmpC (20.1 %) and most ceftriaxone-resistant Enterobacterales (<55 %), except E. coli. Ertapenem demonstrated low susceptibility to K. pneumoniae, E. cloacae (both approximately 50 %), and isolates harboring only AmpC genes (57.9 %). A high prevalence and diversity of AmpC genes were observed in E. coli and K. pneumoniae. The limited activity of ertapenem and ceftolozane/tazobactam suggests that the molecular mechanisms underlying ceftriaxone-resistant Enterobacterales in Taiwan are complex and likely involve factors beyond AmpC and ESBL carriage.